8-K: Salarius Annual Meeting Adjourned Due to Lack of Quorum

Salarius Pharmaceuticals adjourned its 2025 Annual Meeting of Stockholders due to insufficient quorum, rescheduling it for December 31, 2025.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) convened its 2025 Annual Meeting of Stockholders on December 19, 2025.
• The meeting was adjourned without conducting any business because a sufficient number of shares were not present or represented by proxy to constitute a quorum.
• The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to vote.
• Approximately 30% of shares of the company's common stock were represented by proxy at the time the meeting was adjourned.
• The Annual Meeting will reconvene virtually on December 31, 2025, at 10:00 a.m. Central Time.
• The record date for determining stockholder eligibility to vote remains October 24, 2025, and proxies previously submitted will be voted unless properly revoked.

Sentiment

Score: 4

Explanation: The adjournment of the annual meeting due to a lack of quorum is a negative administrative event, indicating low shareholder engagement. However, the underlying business activities of Salarius and its subsidiary Decoy, including ongoing clinical trials and successful capital attraction for Decoy, provide some offsetting positive context, preventing a lower score.

Positives

• Salarius's subsidiary, Decoy Therapeutics Inc., has attracted financing from institutional investors, the Massachusetts Life Sciences Seed Fund, the Google AI startup program, and the NVIDIA Inception program.
• Decoy Therapeutics is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer, and manufacture peptide conjugate drug candidates, initially focused on respiratory viruses and GI cancers.
• Salarius continues to advance its clinical-stage drug candidates, including seclidemstat (in a Phase 1/2 clinical study for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)) and SP-3164 (an IND-stage oral small molecule protein degrader).
• Seclidemstat previously received financial support from the National Pediatric Cancer Foundation and a Product Development Award from the Cancer Prevention and Research Institute of Texas.

Negatives

• The 2025 Annual Meeting of Stockholders was adjourned due to a failure to meet the required 34% quorum, with only approximately 30% of shares represented by proxy.
• This administrative delay prevents the company from conducting scheduled business and requires additional effort to solicit votes for the reconvened meeting.

Risks

• Failure to achieve quorum at the reconvened Annual Meeting could further delay critical corporate governance matters and stockholder decisions.
• Low stockholder engagement, as evidenced by the lack of quorum, could indicate broader investor disinterest or dissatisfaction.

Future Outlook

The 2025 Annual Meeting of Stockholders is scheduled to reconvene virtually on December 31, 2025, to address the proposals outlined in the definitive proxy statement. The company is actively soliciting additional votes to ensure a quorum is met at the reconvened meeting.

Management Comments

• Salarius Pharmaceuticals, Inc. announced that its 2025 Annual Meeting of Stockholders scheduled for and convened on December 19, 2025, has been adjourned for the purpose of soliciting additional votes.
• The company encourages all stockholders to review the Definitive Proxy Statement, along with all other related proxy materials, which are available free of charge on the SEC's website.
• Stockholders as of the close of business on October 24, 2025, the record date for the Annual Meeting, are encouraged to vote as soon as possible.

Industry Context

Salarius Pharmaceuticals operates in the clinical-stage biopharmaceutical sector, focusing on developing cancer treatments. Its subsidiary, Decoy Therapeutics, is a preclinical-stage biotechnology company utilizing advanced ML and AI tools for drug discovery, specifically targeting respiratory viruses and GI cancers, reflecting a broader industry trend towards AI-driven drug development and diversification into infectious diseases.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience a delay in voting on company proposals and may need to take further action to submit proxies for the reconvened meeting. The low quorum suggests potential disengagement or dissatisfaction among some investors.

Next Steps

• The 2025 Annual Meeting of Stockholders will reconvene virtually on December 31, 2025, at 10:00 a.m. Central Time.
• The company and its proxy solicitor, Alliance Advisors, will continue to solicit additional votes from stockholders to ensure a quorum is met.

Key Dates

Keywords

Salarius Pharmaceuticals, SLRX, Annual Meeting, Stockholders Meeting, Quorum, Adjournment, Proxy Solicitation, Corporate Governance, Biopharmaceutical, Cancer Treatment, MDS, CMML, Decoy Therapeutics, Peptide Conjugates, AI in Biotech, SEC Filing, 8-K